Enovis Corporation $ENOV Stake Increased by Front Street Capital Management Inc.

Front Street Capital Management Inc. boosted its stake in Enovis Corporation (NYSE:ENOV) by 106.1% during the 1st quarter, HoldingsChannel reports. The fund owned 746,056 shares of the company’s stock after buying an additional 384,124 shares during the period. Enovis comprises 2.2% of Front Street Capital Management Inc.’s portfolio, making the stock its 18th largest position. Front Street Capital Management Inc.’s holdings in Enovis were worth $16,973,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Arax Advisory Partners bought a new stake in shares of Enovis in the 4th quarter worth about $29,000. EverSource Wealth Advisors LLC lifted its position in shares of Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares during the last quarter. Danske Bank A S acquired a new position in Enovis in the third quarter worth about $64,000. iSAM Funds UK Ltd bought a new stake in Enovis in the third quarter valued at about $80,000. Finally, Brown Brothers Harriman & Co. bought a new stake in Enovis in the third quarter valued at about $90,000. 98.45% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have issued reports on ENOV. BTIG Research restated a “buy” rating and set a $39.00 price objective on shares of Enovis in a research note on Friday, May 22nd. Weiss Ratings upgraded shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 21st. Wells Fargo & Company reduced their price target on shares of Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a report on Friday, May 8th. William Blair started coverage on Enovis in a research report on Friday, April 17th. They set an “outperform” rating for the company. Finally, Evercore set a $32.00 target price on Enovis in a research report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $41.86.

Insider Activity at Enovis

In other news, insider Oliver Engert acquired 1,200 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were bought at an average price of $21.62 per share, with a total value of $25,944.00. Following the purchase, the insider owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. This represents a 2.37% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders acquired 4,200 shares of company stock valued at $92,084. 2.90% of the stock is currently owned by insiders.

Enovis Price Performance

NYSE ENOV opened at $29.32 on Friday. Enovis Corporation has a 12 month low of $19.14 and a 12 month high of $34.28. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.04 and a quick ratio of 1.05. The firm has a market capitalization of $1.69 billion, a PE ratio of -1.47 and a beta of 1.39. The company’s 50 day simple moving average is $23.96 and its 200 day simple moving average is $23.78.

Enovis (NYSE:ENOV) last released its earnings results on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, topping analysts’ consensus estimates of $0.82 by $0.07. The firm had revenue of $589.15 million during the quarter, compared to the consensus estimate of $572.02 million. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.81 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities research analysts forecast that Enovis Corporation will post 3.12 EPS for the current fiscal year.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.